Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes - Wikidata - awgldk - TriplyDB

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes

http://www.wikidata.org/entity/Q33607755

about

Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice.Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study.Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.

P2860

Q28071764-683DFC03-36DA-4689-9554-CE3145BB3AFD Q35087917-13681E1D-9872-4BCB-BAF6-A113E78E1E32 Q36124544-00415B61-FC61-453D-96EC-9EF71F41E9E3 Q37063273-94375887-A151-4516-BF61-59491E3CB0D1 Q38716033-D1A0F4BF-8FD7-4FCC-AEEA-7FB243DC6893 Q38795046-919C7863-4622-4C86-843B-DF126B4ECFE3 Q40487459-CE5AA54F-8733-4AF4-A31D-437B7357D113 Q41259354-B1C08BDD-6253-424D-8A76-66A0F39BC850 Q47140737-6F4025EE-2DB6-4C4E-BF92-C680CB3D9C2E Q47918382-C72A7A1F-8ECF-4A81-8A44-20E8AB41794B Q51226655-03F6BAFD-8150-464C-B030-C1CE5FA0B622

P2860

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes

http://www.wikidata.org/entity/Q33607755

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Sitagliptin added to voglibose ...... patients with type 2 diabetes

@ast

Sitagliptin added to voglibose ...... patients with type 2 diabetes

@en

type

label

Sitagliptin added to voglibose ...... patients with type 2 diabetes

@ast

Sitagliptin added to voglibose ...... patients with type 2 diabetes

@en

prefLabel

Sitagliptin added to voglibose ...... patients with type 2 diabetes

@ast

Sitagliptin added to voglibose ...... patients with type 2 diabetes

@en

P1433

Q33607755-F6179935-5C38-4991-B607-CA2F12FA2341

P1476

Q33607755-998723AA-3EEA-46BC-BA3D-BB9EDF2C6133

P2093

Q33607755-19DD694A-B89E-48FB-ADD3-4429E07AF9AC

Q33607755-2CFA93D5-1EF8-49B1-9645-92300B98E08D

Q33607755-4D6702D4-E8AC-4409-A43E-453620F1E5EB

Q33607755-634099B4-4DCE-4321-9619-A0CA4C76F6C2

Q33607755-645F5D15-708A-4E8A-99C5-0B741840735F

Q33607755-81B13031-270A-4A7E-BF0C-8E2F6A4C1C3B

Q33607755-AA488EE3-9C44-460E-B1B6-025C9FF63CF5

P2860

Q33607755-05019DCF-FDC6-4EEF-9195-3CA61F97942F

Q33607755-0C1E04A4-1DA4-41AE-8D6D-95A2D47D450F

Q33607755-13A8E6BC-5687-4374-BF5A-5594C379A0BD

Q33607755-1CD36BC1-8497-424F-BCB2-5AA80523FE0C

Q33607755-32E8FF96-911F-494D-BD40-2F890A1FCC70

Q33607755-3C2D1E82-B0E3-4EF1-9EE2-C699CB2508D9

Q33607755-47C7469C-618D-468A-AF6E-46EEC5348A00

Q33607755-50B52C73-776B-4D30-AFDA-F127A62CE256

Q33607755-580FFD4A-3AD7-4469-A223-E6D2ACA7171B

Q33607755-6A709C0C-6932-4A87-8EE3-C8302697802C

P304

Q33607755-06E22EDE-64A9-42E5-942C-534A036E5F84

P31

Q33607755-E3A5F117-49A3-4CD1-BCCA-CB6030F52DA1

P356

Q33607755-43C71696-448B-4348-9307-B533D07AB49E

P433

Q33607755-AADB8190-9013-4A86-8EED-CB29E04CEA2D

P478

Q33607755-1BB8FAF0-1ECE-47A2-82BC-4B77A7D75765

P577

Q33607755-3C0B7E27-53F8-4829-8CC4-16733CC799C2

P5875

Q33607755-713BD9BE-FBDE-4783-B7F1-C77F3AAEC6AA

P698

Q33607755-817B13BD-92A6-4D9A-8887-615771B949E7

P921

Q33607755-9B66AA4F-4348-4284-8110-3BFDA9DCD49D

P932

Q33607755-D516B823-B4EA-4A7B-82B8-2D96A2FC57D1

P356

P1433

Journal of Diabetes Investigation

P1476

Sitagliptin added to voglibose ...... patients with type 2 diabetes

@en

P2093

Asako Sato

http://www.w3.org/2001/XMLSchema#string

Juan Camilo Arjona Ferreira

http://www.w3.org/2001/XMLSchema#string

Kotoba Okuyama

http://www.w3.org/2001/XMLSchema#string

Naoko Tajima

http://www.w3.org/2001/XMLSchema#string

Takashi Kadowaki

http://www.w3.org/2001/XMLSchema#string

Taro Okamoto

http://www.w3.org/2001/XMLSchema#string

Toshiomi Minamide

http://www.w3.org/2001/XMLSchema#string

P2860

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Biology of incretins: GLP-1 and GIP

International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.

P304

595-604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDI.12116

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259552819

http://www.w3.org/2001/XMLSchema#string

P698

24843714

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4020255

http://www.w3.org/2001/XMLSchema#string